
The hardening medical stop-loss market: A catalyst for captive growth
Phillip Giles, of Skyward Specialty Insurance, takes a look at the medical stop-loss part of the employee benefits market.
For the first time in more than a quarter century, the medical stop-loss (MSL) market appears to be entering a period of meaningful and sustained rate firming. A convergence of deteriorating underwriting performance, increasing claim severity, rising healthcare costs and tightening reinsurance capacity is fundamentally changing its underpinning economics.
That shift has significant implications for self-funded employers, particularly smaller and midsize organisations. As traditional stop-loss capacity becomes more expensive and underwriting more restrictive, group medical stop-loss captives are positioned for accelerated growth. The rationale is straightforward: a captive provides a more sophisticated and stable mechanism for assuming, sharing and transferring risk, retaining the more predictable components of healthcare exposure while transferring catastrophic and genuinely unpredictable layers to the insurance and reinsurance markets.
A market at an inflection point
Annual medical stop-loss premium volume has expanded from approximately $8 billion in 2010 to an estimated $50 billion today. That extraordinary growth, however, has been accompanied by steadily deteriorating underwriting performance.
According to NAIC data1, Industry-wide gross loss ratios have trended upward for much of the past decade, reaching nearly 86% in 2024, the most recently reported underwriting period. Importantly, these are gross, not net, loss ratios. After acquisition, administrative, operational and other expenses, those results suggest portions of the market are operating at or near unprofitable combined ratios.
Carriers responded with more disciplined underwriting and corrective pricing during 2025. Nevertheless, preliminary NAIC market data1 indicates underlying results continued to deteriorate, with the industry-wide loss ratio exceeding 90%.
The significance extends beyond higher stop-loss premiums. The market is beginning to reprice previously underpriced risk. For employers, traditional stop-loss might therefore no longer provide the degree of competitive rate stability and predictability that characterised much of the MSL market over the past 25 years.
The economics of risk transfer are changing
A fundamental principle of alternative risk has always been simple: transfer risk in a soft market; retain risk in a hard market.
Insurance is most economically valuable when it protects against losses that are uncertain, volatile or financially disruptive. As a risk becomes more predictable, however, it can be increasingly economically rational to retain that exposure and budget for its expected cost rather than pay an insurer to assume it, along with the associated acquisition expenses, capital costs and profit margin. The objective is to optimise the balance between risk retention and risk transfer.
Large employers have historically had greater flexibility to achieve that balance. With stronger balance sheets, larger and more diversified employee populations and greater claims credibility, they can absorb more volatility and retain higher layers of healthcare risk.
Smaller and midsize employers face a different capital constraint. They might recognise the economic advantages of self-funding but lack the financial capacity to absorb large individual claims without materially disrupting their budgets. This is where group medical stop-loss captives become particularly compelling.
Captives as a risk-stabilisation mechanism
A group medical stop-loss captive changes the architecture of risk financing. Participating employers retain and share defined layers of risk within a diversified pool while transferring the most volatile and catastrophic exposures to the external insurance and reinsurance markets.
For smaller self-funded employers, this structure can materially enhance both the financial efficiency and stability of self-funding. Diversification through pooled risk sharing can reduce the impact of individual claim volatility, while centralised underwriting and improved claims data can provide a more sophisticated view of underlying risk than might be available to an individual employer.
Captive participation can also provide access to medical cost-containment, clinical management and risk-reduction strategies that smaller employers might struggle to develop or implement independently.
The captive does not eliminate risk; it changes the economics of financing it by aggregating and diversifying exposure and allocating it more deliberately. That distinction becomes particularly important as the traditional stop-loss market hardens.
The opportunity for smaller and midsize employers
A hardening stop-loss market might accelerate captive adoption by fundamentally changing the relative value proposition.
In a soft market, traditional stop-loss can be sufficiently inexpensive that transferring a larger proportion of risk is economically attractive. When capacity is abundant and pricing competitive, the additional infrastructure and risk-sharing associated with a captive might offer less incremental value.
A hard market changes that equation. As premiums increase, attachment points rise, underwriting becomes more restrictive and renewal volatility increases, employers have greater incentive to reconsider how much risk they should transfer and how much they should retain.
For large employers, self-funding and single-parent captives have long been viable alternatives. The more significant growth opportunity now lies with smaller and midsize employers that historically lacked the scale or financial capacity to retain meaningful levels of healthcare risk.
A group captive allows these employers to aggregate exposures with other carefully selected organisations, creating diversification and economies of scale that would be difficult to achieve independently. In this context, the captive is more than another stop-loss product. It is a risk-financing architecture that can make self-funding more sustainable for employers that otherwise might stay heavily dependent on the traditional insurance market.
Disciplined captives will separate themselves
Not all captives will produce the same results. Long-term performance depends on disciplined membership selection, prudent underwriting, effective governance and a meaningful commitment to reducing medical costs and risks.
The strongest captives will not pursue scale for its own sake. They will emphasise quality of risk, alignment among members, underwriting discipline and sustainable performance across the insurance cycle. A captive that simply aggregates risk without addressing the underlying drivers of healthcare costs is unlikely to produce durable results.
Conversely, a captive that combines disciplined underwriting with sophisticated clinical management, cost-containment strategies, data transparency and active member engagement has the potential to outperform the traditional stop-loss market over time.
The appropriate measure of success is not whether a captive produces the lowest rate in a particular year. It is whether it delivers sustainable, risk-adjusted value and greater long-term rate stability.
From risk transfer to risk optimisation
The evolution of medical stop-loss captives reflects a broader shift in how employers should approach healthcare risk.
The objective is neither to transfer risk whenever it becomes uncomfortable nor to retain risk simply because insurance has become expensive. It is to optimise risk allocation.
Employers should retain those portions of their healthcare exposure that are reasonably predictable and economically manageable, while transferring catastrophic and genuinely unpredictable layers to insurance and reinsurance markets designed to absorb them.
As traditional stop-loss pricing continues to firm, the economic value of that approach becomes increasingly apparent. For larger employers, it could mean increasing levels of risk retention. For smaller and midsize employers, it might mean accelerated adoption of group medical stop-loss captives to access the economic benefits of greater risk retention without assuming an unacceptable level of individual employer volatility.
As the stop-loss market continues to harden, captives are likely to become increasingly relevant to high-quality self-funded employers seeking to manage volatility, improve long-term rate predictability and exert greater control over the economics of their healthcare risk.
For an increasing number of smaller and mid-size self-funded employers, the answer might be a group medical stop-loss captive.
About the author:
Phillip C. Giles is the chief growth officer for Skyward Specialty’s accident and health division. He has 40 years of medical stop-loss and captive experience. He can be contacted at: pgiles@skywardinsurance.com
Did you get value from this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
